Market Newsdesk

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Interface, Inc. (NASDAQ: TILE) between March 2, 2018 and September 28, 2020, inclusive (the “Class Period”) of the important January 11, 2021 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Interface investors under the federal securities laws.

To join the Interface class action, go to http://www.rosenlegal.com/cases-register-1788.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Interface had inadequate disclosure controls and procedures and internal control over financial reporting; (2) consequently, Interface, among other things, reported artificially inflated income and earnings per share (EPS) in 2015 and 2016; (3) Interface and certain of its employees were under investigation by the SEC with respect to the foregoing since at least November 2017, had impeded the SEC’s investigation, and downplayed the true scope of Interface’s wrongdoing and liability with respect to the SEC investigation; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 11, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1788.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        [email protected]
        [email protected]
        www.rosenlegal.com

FORT WASHINGTON, Pa., Dec. 09, 2020 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL) (www.TollBrothers.com), the nation’s leading builder of luxury homes, today announced that its Board of Directors has approved a quarterly cash dividend to shareholders. The dividend of $0.11 per share will be paid on January 22, 2021 to shareholders of record on the close of business on January 8, 2021.

Toll Brothers, Inc., A FORTUNE 500 Company, is the nation’s leading builder of luxury homes. The Company began business over fifty years ago in 1967 and became a public company in 1986. Its common stock is listed on the New York Stock Exchange under the symbol “TOL.” The Company serves first-time, move-up, empty-nester, active-adult, affordable luxury and second-home buyers, as well as urban and suburban renters. It operates in 24 states: Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Maryland, Massachusetts, Michigan, Nevada, New Jersey, New York, North Carolina, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, and Washington, as well as in the District of Columbia.

Toll Brothers builds an array of luxury residential single-family detached, attached home, master planned resort-style golf, and urban low-, mid-, and high-rise communities, principally on land it develops and improves. The Company acquires and develops rental apartment and commercial properties through Toll Brothers Apartment Living, Toll Brothers Campus Living, and the affiliated Toll Brothers Realty Trust, and develops urban low-, mid-, and high-rise for-sale condominiums through Toll Brothers City Living. The Company operates its own architectural, engineering, mortgage, title, land development and land sale, golf course development and management, and landscape subsidiaries. Toll Brothers operates its own alarm monitoring company through TBI Smart Home Solutions, a complete home technology division. In addition to providing security monitoring, TBI Smart Home Solutions offers homeowners a full range of low voltage options, allowing buyers to maximize the potential of technology in their new home. The Company also operates its own lumber distribution, house component assembly, and manufacturing operations. Through its Gibraltar Real Estate Capital joint venture, the Company provides builders and developers with land banking, non-recourse debt and equity capital.

In 2020, Toll Brothers was named World’s Most Admired Home Building Company in Fortune magazine’s survey of the World’s Most Admired Companies®, the sixth year in a row it has been so honored. Toll Brothers has won numerous other awards, including Builder of the Year from both Professional Builder magazine and Builder magazine, the first two-time recipient from Builder magazine. The Company sponsors the Toll Brothers Metropolitan Opera International Radio Network, bringing opera to neighborhoods throughout the world. For more information visit www.TollBrothers.com.

Toll Brothers discloses information about its business and financial performance and other matters, and provides links to its securities filings, notices of investor events, and earnings and other news releases, on the Investor Relations section of its website (investors.TollBrothers.com).

Forward-Looking Statements

This release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. One can identify these statements by the fact that they do not relate to matters of a strictly historical or factual nature and generally discuss or relate to future events. These statements contain words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “may,” “can,” “could,” “might,” “should,” “likely,” “will,” and other words or phrases of similar meaning. Such statements may include, but are not limited to, information and statements regarding: the impact of Covid-19 on the U.S. economy, the markets in which we operate or may operate, and on our business; our strategic priorities; our land acquisition, land development and capital allocation priorities; market conditions; demand for our homes; anticipated operating results and guidance; home deliveries; financial resources and condition; changes in revenues; changes in profitability; changes in margins; changes in accounting treatment; cost of revenues, including expected labor and material costs; selling, general, and administrative expenses; interest expense; inventory write-downs; home warranty and construction defect claims; unrecognized tax benefits; anticipated tax refunds; sales paces and prices; effects of home buyer cancellations; growth and expansion; joint ventures in which we are involved; anticipated results from our investments in unconsolidated entities; our ability to acquire or dispose of land and pursue real estate opportunities; our ability to gain approvals and open new communities; our ability to market, construct and sell homes and properties; our ability to deliver homes from backlog; our ability to secure materials and subcontractors; our ability to produce the liquidity and capital necessary to conduct normal business operations or to expand and take advantage of opportunities; and the outcome of legal proceedings, investigations, and claims.

Any or all of the forward-looking statements included in this release are not guarantees of future performance and may turn out to be inaccurate. This can occur as a result of incorrect assumptions or as a consequence of known or unknown risks and uncertainties. The major risks and uncertainties – and assumptions that are made – that affect our business and may cause actual results to differ from these forward-looking statements include, but are not limited to:

• the effects of the ongoing Covid-19 pandemic, which are highly uncertain, cannot be predicted and will depend upon future developments, including the severity of Covid-19 and the duration of the outbreak, the duration of existing social distancing and shelter-in-place orders, further mitigation strategies taken by applicable government authorities, the availability of a vaccine, adequate testing and therapeutic treatments and the prevalence of widespread immunity to Covid-19;
• the effect of general economic conditions, including employment rates, housing starts, interest rate levels, availability of financing for home mortgages and strength of the U.S. dollar;
• market demand for our products, which is related to the strength of the various U.S. business segments and U.S. and international economic conditions;
• the availability of desirable and reasonably priced land and our ability to control, purchase, hold and develop such parcels;
• access to adequate capital on acceptable terms;
• geographic concentration of our operations;
• levels of competition;
• raw material and labor prices and availability;
• the effect of U.S. trade policies, including the imposition of tariffs and duties on home building products and retaliatory measures taken by other countries;
• the effects of weather and the risk of loss from earthquakes, volcanoes, fires, floods, droughts, windstorms, hurricanes, pest infestations and other natural disasters, and the risk of delays, reduced consumer demand, and shortages and price increases in labor or materials associated with such natural disasters;
• the risk of loss from acts of war, terrorism or outbreaks of contagious diseases, such as Covid-19;
• transportation costs;
• federal and state tax policies;
• the effect of land use, environment and other governmental laws and regulations;
• legal proceedings or disputes and the adequacy of reserves;
• risks relating to any unforeseen changes to or effects on liabilities, future capital expenditures, revenues, expenses, earnings, indebtedness, financial condition, losses and future prospects;
• changes in accounting principles;
• risks related to unauthorized access to our computer systems, theft of our homebuyers’ confidential information or other forms of cyber-attack; and
• other factors described in “Risk Factors” included in our Annual Report on Form 10-K for the year ended October 31, 2019 and in subsequent filings we make with the Securities and Exchange Commission (“SEC”).

Many of the factors mentioned above or in other reports or public statements made by us will be important in determining our future performance. Consequently, actual results may differ materially from those that might be anticipated from our forward-looking statements.

Forward-looking statements speak only as of the date they are made. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

For a more detailed discussion of these factors, see the information under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our most recent Annual Report on Form 10-K filed with the SEC and in subsequent reports filed with the SEC.

CONTACT: Frederick N. Cooper (215) 938-8312
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d33a542c-616e-4cb1-bf93-bc30cbc7fd11

• First time an antigen presenting cell (APC) activator has shown an Overall Survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune checkpoint inhibitor therapy
• Promising and improving overall trend in OS in total population (based on approx. 60% of events): median survival benefit of +2.7 months from efti plus chemotherapy, compared to chemotherapy plus placebo
• Statistically significant OS benefit in efti group observed in pre-defined patient groups:
  • +7.1 months survival benefit (median of 21.9 vs. 14.8 months, nearly 50% longer) from efti with chemotherapy for patients under 65 years of age
  • +9.4 months survival benefit (median of 22.4 vs. 12.9 months, 74% longer) from efti with chemotherapy for patients with a low starting monocyte count
• Statistically significant increase in CD8 T cells in patients treated with efti plus chemotherapy, correlated with prolonged OS, indicating pharmacodynamic activity and proof of concept of efti’s mode of action 
• Collection of OS data ongoing, with final data expected to be reported mid 2021
• Investor webcast to discuss survival data scheduled for Friday, 11 December 2020, at 8.30 am Australian Eastern Daylight Time, details below

Sydney, AUSTRALIA, Dec. 10, 2020 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to report encouraging first Overall Survival (OS) follow up data from its ongoing Phase IIb AIPAC study evaluating Immutep’s lead product candidate eftilagimod alpha in combination with paclitaxel chemotherapy (“efti group”) in comparison to a combination of placebo and paclitaxel chemotherapy (“comparator group”) in patients with HER2-negative/HR positive metastatic breast cancer (HR+ MBC). These data were selected to be presented in a spotlight presentation at the San Antonio Breast Cancer Symposium 2020, which is being held virtually this week from Texas, USA.

AIPAC Principal Investigator, Hans Wildiers of University Hospital Leuven, Leuven, Belgium, said: 
“Improving Overall Survival is a key endpoint when evaluating the benefit of new anticancer drugs. Efti is a new drug targeting the immune system in an innovative way and has the potential to improve outcomes in HER2-negative/hormone receptor positive metastatic breast cancer patients. The AIPAC study investigated efti in combination with first line chemotherapy in this population, a group of about 250,000 patients diagnosed worldwide each year. Although the progression free survival data in the efti group did not show a significant improvement versus the comparator arm in AIPAC earlier this year, the OS data in general looks already very interesting and will mature further. The OS data in subgroups such as those below age 65 years are highly encouraging and may lead to more effective treatment options for metastatic breast cancer patients.”

Immutep CSO and CMO, Dr Frederic Triebel said: “We are very excited to see that efti is boosting the immune system by providing a statistically significant increase in CD8 T cell numbers, which is correlated with prolonged survival for patients. These data provide proof-of-concept and support our long-held belief that efti can provide a meaningful benefit to patients in a range of cancer settings by “pushing the gas” on the body’s immune system, representing an important landmark. Through this mechanism, efti is helping a large proportion of patients in the AIPAC study with Her2^–HR⁺ metastatic breast cancer which is typically a non-immunogenic cancer and is therefore significantly less responsive to modern immune checkpoint inhibitor (ICI) therapies. As such, chemotherapy continues to be the standard of care in many instances and there continues to be a large unmet medical need. We look forward to reporting final survival data in 2021.”

Immutep CEO, Marc Voigt said: “AIPAC marks an important milestone for Immutep and builds our confidence that efti is beneficial for many cancer patients, including those with metastatic breast cancer. Notably, we have seen a more material OS benefit than PFS benefit in this study; however, we note that this is not unusual for some immunotherapies where it can take time for the body’s immune system to be boosted and provide a therapeutic benefit. We are very encouraged by these first OS results which, subject to ongoing data collection, warrant a registrational perspective and regulatory interactions towards what we hope will be an important new class of medicines.”

Key Efficacy Results: data cut-off 24 September 2020

In the total patient population, first OS data (based on approx. 60% of events) show that patients in the efti group had an improving OS trend with a median OS of 20.2 months compared to 17.5 months for patients in the comparator group, indicating a survival benefit of +2.7 months (HR = 0.83; p = 0.14). The OS analysis is based on a 2-sided false positive probability of 0.05. Furthermore, a significant deterioration in quality of life was observed for patients in the comparator group at week 25, which was not observed in the efti group. This is an encouraging observation as these types of benefits are supportive of efti being eligible for reimbursement upon marketing approval.

In key predefined patient groups, the study has already demonstrated a statistically significant and clinically relevant OS benefit from treatment with efti in combination with chemotherapy. Patients under the age of 65 years (representing 66.7% of patients in the efti group) reported a median OS of 21.9 months compared to 14.8 months in the comparator group, indicating a survival benefit of +7.1 months (HR = 0.62; p = 0.012) favoring the efti group.

Figure 1 – Kaplan Meyer curve OS for patients < 65 years

The current data suggest that for patients younger than 65 years old, the probability of being alive at three years with efti plus chemotherapy vs. chemotherapy alone is increased by 100%.

Furthermore, patients with a low monocyte count at baseline (representing 21.9% of patients in the efti group) reported a median OS of 22.4 months compared to 12.9 months in the comparator group, indicating a survival benefit of +9.4 months (HR = 0.47; p = 0.02) favoring the efti group.

Trending towards statistical significance, patients with a more aggressive, more immunogenic luminal B type of breast cancer (representing 48.8% of patients in the efti group) reported a median OS of 16.3 months compared to 12.6 months in the comparator group, indicating a beneficial trend of +3.8 months (HR = 0.69; p = 0.077) favoring the efti group. (See Table 1)

Table 1 – Overall Survival in key patient groups

Note: A lower HR, means a reduced risk of death, e.g. by 53% in the low monocyte group.

Immuno Monitoring Results

Importantly, there was a statistically significant, sustained long-term increase in peripheral CD8 T cells in patients in the efti group. This is consistent with the mode of action of efti. There was also a statistically significant correlation between those patients having an increase in the number of CD8 T cells and those having a prolonged OS. This represents a strong proof-of-concept in a randomised, double blinded setting.

Safety

The combination of efti and paclitaxel chemotherapy was overall safe and well tolerated, further building upon efti’s strong safety profile to date.

The presentation poster is available at www.immutep.com/investors-media/presentations.html.

Next Steps

Multivariate analysis of the data is ongoing and final OS data is expected to be reported in mid 2021.

Webcast Details

Immutep will present this AIPAC data in a global webcast for investors, details are as follows:

• Date & Time:     Friday, 11 December 2020, at 8.30 am Australian Eastern Daylight Time (AEDT) (Thursday, December 10^th, at 4:30 p.m. U.S. ET)
• Register:             http://public.viavid.com/index.php?id=142664
• Questions:         Investors are invited to submit questions in advance via [email protected].

A replay of the webcast will also be available at www.immutep.com from the day after the event.

About the AIPAC trial

Active Immunotherapy Paclitaxel (AIPAC) is a multicentre, placebo-controlled, double-blind, 1:1 randomised Phase IIb clinical trial in HER2-negative/HR positive metastatic breast cancer.

The study is evaluating the combination of Immutep’s lead product candidate, eftilagimod alpha (efti, LAG-3Ig or IMP321), and paclitaxel chemotherapy. 227 HER2-negative/HR positive metastatic breast cancer patients are randomised 1:1 to a chemo-immunotherapy arm (efti plus paclitaxel) or to a comparator arm (placebo plus paclitaxel). Patients receive weekly paclitaxel at days 1, 8 and 15, with either efti or placebo injected subcutaneously on days 2 and 16 of each 4-week cycle, repeated for 6 cycles. Thereafter, patients pass over to the maintenance phase with efti alone.

For more information regarding the AIPAC trial, visit clinicaltrials.gov (identifier NCT02614833) and https://www.ncbi.nlm.nih.gov/pubmed/30977393).

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; [email protected]

U.S. Media:

Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; [email protected]

SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) — Leading Edge Jet Center (“LEJC”), a provider of business aviation services throughout the Pacific Northwest, today announced the introduction of Sustainable Aviation Fuel (“SAF”) to its Fixed Base Operator (“FBO”) facility (“LEJC BFI”) at the King County International Airport-Boeing Field (“BFI”) in Seattle, Washington, one of the busiest general aviation airports in the United States, in partnership with Avfuel, a leading supplier of aviation fuel and services globally.

“We are proud to be a first mover in offering sustainable aviation fuel at BFI, contributing to Seattle’s goal of reducing total greenhouse gas emissions 58% by 2030, said Steven Levesque, Leading Edge Jet Center’s Executive Chairman. “Leading Edge Jet Center provides customers with outstanding service, convenient facilities, seamless transportation, quality maintenance and now direct access to more sustainable air travel.”

LEJC BFI was established in September 2020 with the acquisition of Kenmore Aero Services LLC, which now operates under the LEJC brand and vision for quality, service and innovation in business aviation. With this latest initiative, LEJC is positioning BFI as the first FBO in the state of Washington to offer the green alternative. Together, LEJC and Avfuel will provide customers with an approximately 7,300-gallon load of blended sustainable aviation fuel. SAF is estimated to have an 80% lower carbon footprint than conventional jet fuel, making it an important part of the aviation sector’s long-term strategy to reduce its greenhouse gas emissions.

Scott Helms, LEJC BFI’s General Manager, added, “We are delighted to provide our growing customer base with a high quality, green alternative to traditional jet fuel and to help advance the U.S. aviation industry’s environmental stewardship.”

At BFI, LEJC offers approximately 60,000 square feet of Class A hangar space alongside best-in-class aviation ground services for customers and their aircraft and is developing a new executive terminal and hangar facilities to meet growing demand. Founded in 2005 and established as a standalone company in 2019, LEJC also provides business aviation and jet fueling services at the Redmond Roberts Field Airport and Bend Municipal Airport in Central Oregon and is seeking opportunities to expand its platform in other regional hubs.

“We’re proud to work with Leading Edge Jet Center to make sustainable aviation fuel available to our airport users,” said John Parrott, director of King County International Airport-Boeing Field. “It’s a small but significant step toward supporting King County’s Strategic Climate Action Plan.”

About Leading Edge Jet Center

Leading Edge Jet Center delivers world-class business aviation and jet fueling services in the Pacific Northwest with bespoke customer care that focuses on providing a seamless travel experience. Offering a range of amenities from aircraft maintenance and storage, to ground transportation and hotel bookings, our passion for elevating the travel experience fuels a deep commitment to our clients and our communities. As a trusted aviation partner, Leading Edge Jet Center prides itself on delivering safe, comfortable and reliable service in all facets of our operations as we enable our customers and their businesses to soar to new heights. For more information on Leading Edge Jet Center’s Oregon facilities, please visit www.LeadingEdgeJet.com, or follow us on LinkedIn to receive all the latest updates.

Contact
:

Steven Levesque, Executive Chairman
Leading Edge Jet Center
(843) 412-6881
[email protected] 

VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) — New Pacific Metals Corp. (“New Pacific” or the “Company”) is pleased to announce that Dr. Rui Feng, founder, director and former CEO of the Company, has donated 80,000 shares of the Company to St. Paul’s Foundation of Vancouver and 35,000 shares of the Company to the Viola Desmond Chair in Social Justice at Cape Breton University in Nova Scotia.

St. Paul’s Foundation

Teams at St. Paul’s Hospital are undertaking high-impact COVID-19 research to understand the unprecedented variety of complications; and severe and lasting consequences for a patient’s lungs, heart, kidneys, brain, nervous system, and psychiatric health. This research is key to informing immediate patient care for the best possible health outcomes.

In recent months, St. Paul’s Hospital in Vancouver has been leading research efforts in Canada for better understanding the long-term effects of COVID-19. In May 2020, after just one month of planning and logistics, St. Paul’s launched its post-COVID respiratory clinic and research program.  By September, the clinic encompassed a team of specialists working together across disciplines to address the full scope of post-COVID illness.

“Life-saving research into COVID-19 at St. Paul’s Hospital will have a national impact,” says Dick Vollet, President and CEO, St. Paul’s Foundation. “This generous gift from Dr. Feng will support continued research and innovation to help find more efficient ways to treat the virus and ultimately improve the quality of life for our patients.”

The Viola Desmond Chair in Social Justice

Viola Desmond’s remarkable stand against racial segregation in 1946 is a story which has become an inspiration to all Canadians. In November 2018, Desmond made history by becoming the first Canadian female to appear on the Canadian $10 bill, cementing herself as a symbol of courage to Canadians everywhere.

The Viola Desmond Chair in Social Justice at Cape Breton University (“CBU”) will honour the legacy of Desmond through research and educational initiatives promoting social justice and African Canadian studies in Canada.

“On behalf of the Board of Governors, faculty, staff and students at Cape Breton University, I would like to extend our deepest thanks and gratitude to Dr. Feng for his generous support of our Viola Desmond Chair in Social Justice at CBU,” says President & Vice-Chancellor, David Dingwall. “Through the work of this Chair, we will continue to honour the legacy of social rights activist, Viola Desmond, through education, research and the promotion of social justice and African Canadian studies in Canada.”

ABOUT NEW PACIFIC

New Pacific is a Canadian exploration and development company which owns the Silver Sand Project, in the Potosi Department of Bolivia and the Silverstrike Project in Bolivia.

For further information,
please
contact:

New Pacific Metals Corp.
Gordon Neal
President
Phone: (604) 633-1368
Fax: (604) 669-9387
[email protected]
www.newpacificmetals.com

DALLAS, Dec. 09, 2020 (GLOBE NEWSWIRE) — On December 8, 2020 the North Dallas Bank & Trust Co. (NODB) Board of Directors declared a regular dividend of $0.25 per share and a special dividend of $0.30 per share. The dividends are payable to shareholders of record as of December 23, 2020 and will be paid on December 31, 2020.

North Dallas Bank & Trust Co. is an independent bank established in 1961 with current locations in 5 locations in the Dallas, Texas area. The current dividends are based on North Dallas Bank & Trust Co.’s current financial condition and are not a guarantee that dividends will continue to be paid in the future. For further information about North Dallas Bank & Trust Co., contact Glenn Henry, Chief Financial Officer.

Assets $1.4 Billion

Contact:
Glenn Henry, EVP and CFO
972.716.7100